| DVL1 |
Homo sapiens |
|
DVL1 is differentially expressed in 89 experiments [77 up/86 dn]: 21 organism parts: skeletal muscle [2 up/1 dn], white blood cells [0 up/1 dn], ...; 25 disease states: normal [4 up/5 dn], glioblastoma [0 up/2 dn], ...; 19 cell types, 22 cell lines, 15 compound treatments and 16 other conditions. |
| DVL, DVL1, DVL1L1 |
|
dsh-2 (Caenorhabditis elegans)
dsh-1 (Caenorhabditis elegans)
DVL1_RAT (Rattus norvegicus)
mig-5 (Caenorhabditis elegans)
Dvl1 (Mus musculus)
(Compare orthologs)
|
|
|
| DEP domain, DIX, Dishevelled protein, Dishevelled related protein, PDZ/DHR/GLGF |
|
|
| Wnt receptor signaling pathway, Wnt receptor signaling pathway through beta-catenin, axon, cytoplasmic membrane-bounded vesicle, dendrite morphogenesis |
|
|
|
O14640
P54792
Q6PJD6
Q8NA39
Q86TH3
|
|
|
|
ENSG00000107404
|
|
|
| Factor Value |
Factor |
Up/Down |
Legend: - number of studies the gene is up/down in
|
|
Normal
|
Disease state |
|
|
None
|
Compound treatment |
|
|
Skeletal muscle
|
Organism part |
|
|
PC3
|
Cell line |
|
|
FLAP
|
Compound treatment |
|
|
MK886
|
Compound treatment |
|
|
HNRPA2B
|
Compound treatment |
|
|
Glioblastoma
|
Disease state |
|
|
Estrogen receptor 1 positive; ...
|
Test result |
|
|
Fibroblast
|
Cell type |
|
|
Epithelial cell
|
Cell type |
|
|
HL-60
|
Cell line |
|
|
Monocyte
|
Cell type |
|
|
Acute promyelocytic leukemia
|
Disease state |
|
|
SW480
|
Cell line |
|
|
SW620
|
Cell line |
|
|
SKMEL5
|
Cell line |
|
|
Pretreatment primary sample
|
Clinical info |
|
|
CodeLink Labeling
|
Protocol type |
|
|
Stromal cell
|
Cell type |
|
|
White blood cells
|
Organism part |
|
|
Epilepsy
|
Disease state |
|
|
Enzo Labeling
|
Protocol type |
|
|
Not applicable
|
Histology |
|
|
Breast carcinoma
|
Disease state |
|
|
Benign prostatic hyperplasia
|
Disease state |
|
|
Prostate carcinoma
|
Disease state |
|
|
Primary cells
|
Cell line |
|
|
N/a
|
Test result |
|
|
Lipopolysaccharide
|
Compound treatment |
|
|
Spermatocyte
|
Cell type |
|
|
Vascular smooth muscle cell
|
Cell type |
|
|
Thymus
|
Organism part |
|
|
BL41K3
|
Cell line |
|
|
BJABK3
|
Cell line |
|
|
Atrial mycocardium
|
Organism part |
|
|
Ventricular myocardium
|
Organism part |
|
|
Chondrocyte
|
Cell type |
|
|
SkinEthic keratinocyte
|
Cell type |
|
|
Epidermal keratinocyte
|
Cell type |
|
|
Caudate nucleus
|
Organism part |
|
|
Teratozoospermia
|
Disease state |
|
|
Normospermic
|
Disease state |
|
|
Glucocorticoid sensitive
|
Phenotype |
|
|
Muscle invasive carcinoma
|
Disease state |
|
|
Methotrexate
|
Compound treatment |
|
|
X-linked chronic granulomatous
|
Disease state |
|
|
Gastric cancer
|
Disease state |
|
|
Keratinocyte
|
Cell type |
|
|
Hypericin incubated, not irrad...
|
Growth condition |
|
|
Hypericin incubated, irradiate...
|
Growth condition |
|
|
Fetal bovine serum in media
|
Growth condition |
|
|
Actinomycin D
|
Compound treatment |
|
|
Grade IV
|
Tumor grading |
|
|
Interferon-gamma + lipopolysac...
|
Compound treatment |
|
|
ERalpha transfected
|
Genotype |
|
|
ERbeta transfected
|
Genotype |
|
|
Cadmium chloride 2.5-hydrate
|
Compound treatment |
|
|
M1 macrophage
|
Cell type |
|
|
Trichostatin A
|
Compound treatment |
|
|
Acute lymphocytic leukemia
|
Disease state |
|
|
WE 68
|
Cell line |
|
|
Uterus corpus
|
Organism part |
|
|
Heregulin
|
Compound treatment |
|
|
Testis
|
Organism part |
|
|
BJAB
|
Cell line |
|
|
Normal
|
Histology |
|
|
Bone marrow
|
Organism part |
|
|
Astrocytoma
|
Disease state |
|
|
0 cm away from the tumor bound...
|
Observation |
|
|
Seminiferous tubule
|
Organism part |
|
|
Baseline uninfected
|
Disease state |
|
|
Carcinoma in situ lesion
|
Disease state |
|
|
Atrioventricular node
|
Organism part |
|
|
MDA-MB-231
|
Cell line |
|
|
Rapamycin
|
Compound treatment |
|
|
Papillary thyroid carcinoma
|
Disease state |
|
|
Frontal cortex, superior motor...
|
Organism part |
|
|
Affymetrix Labeling
|
Protocol type |
|
|
A549
|
Cell line |
|
|
U937
|
Cell line |
|
|
Tumor
|
Organism part |
|
|
Cartilage
|
Organism part |
|
|
Appendix
|
Organism part |
|
|
Leydig cell
|
Cell type |
|
|
Cancer17
|
Replicate |
|
|
Prostate cancer
|
Disease state |
|
|
Burkitt's lymphoma
|
Disease state |
|
|
TIVE
|
Cell line |
|
|
Primary fibroblast
|
Cell type |
|
|
HPL1
|
Cell line |
|
|
Primary
|
Disease staging |
|
|
Lymph node metastasis
|
Disease staging |
|
|
Adult
|
Developmental stage |
|
|
Infant
|
Developmental stage |
|
|
Johnsen score count 10: full s...
|
Histology |
|
|
Johnsen score count 7: many ea...
|
Histology |
|
|
Control
|
RNAi |
|
|
SIM2s
|
RNAi |
|
|
Ovary
|
Organism part |
|
|
HMEC184
|
Cell line |
|
|
White blood cell
|
Cell type |
|
|
Platelet
|
Cell type |
|
|
Peripheral blood mononuclear c...
|
Cell type |
|
|
T cell
|
Cell type |
|
|
Hydroxyurea
|
Compound treatment |
|
|
Empty pBabe transduced
|
Gene modification |
|
|
Endothelial cell
|
Cell type |
|
|
Granulocyte
|
Cell type |
|
|
Invasive ductal carcinoma
|
Histology |
|
|
MCF10A
|
Cell line |
|
|
Cigarette smoke
|
Compound treatment |
|
|
Serum starvation + thymidine b...
|
Growth condition |
|
|
Lymph node
|
Organism part |
|
|
Whole blood
|
Organism part |
|
|
Rapid disease progression
|
Clinical history |
|
|
Cancer13
|
Replicate |
|
|
Beas2B
|
Cell line |
|
|
Aggregatibacter actinomycetemc...
|
Infection |
|
|
Malignant melanoma
|
Disease state |
|
|
Glucocorticoid resistant
|
Phenotype |
|
|
Benign
|
Disease staging |
|
|
SKBR3
|
Cell line |
|
|
Superficial transitional cell ...
|
Disease state |
|
|
Cystic change
|
Histology |
|
|
Prefrontal cortex
|
Organism part |
|
|
Mercury dichloride
|
Compound treatment |
|
|
Endometrioid carcinoma
|
Disease state |
|
|
Peripheral blood
|
Organism part |
|
|
Synovial fluid
|
Organism part |
|
|
T84
|
Cell line |
|
|
Caco-2
|
Cell line |
|
|
Benign nevi
|
Disease state |
|
|
Esophageal adenocarcinoma
|
Disease state |
|
|
Grade III
|
Tumor grading |
|
|
Metastatic
|
Disease staging |
|
|
Acute malaria, natural infecti...
|
Disease state |
|
|
HaCaT
|
Cell line |
|
|
|
|
|
Processing time: 0.122 secs.